Skip to main content


You are here Baltimore: An $11.5M Series C will help Gliknik advance 3 treatments for cancer, autoimmune disease

Friday, June 25, 2021

The University of Maryland BioPark-based company has now raised $81M million total.

Add a company based in Baltimore’s University of Maryland BioPark to this week’s Money Moves.

Gliknik, a company developing treatments for people with cancer and autoimmune diseases, announced completion of its Series C round.

The company raised $11.5 million in a round led by First in Ventures (FIV). Also participating were SAISO Partners, and affiliates of RDA Ventures and Garden Street Holdings.

“We believe that Gliknik has created several potential best-in-class mid-stage assets,” said Scott Roth, managing partner of FIV, in a statement. “This capital will help unlock the potential of these compounds and uniquely positions Gliknik to make a difference for patients with cancer or autoimmune disorders.”

Read the full story from Baltimore.